Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures
Status:
Not yet recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
Phase II, multicenter, open-label, multi-cohort proof-of-concept study designed to evaluate
the safety and efficacy of Ezabenlimab combined with BI 907828 in patients with unresectable,
locally advanced or metastatic solid tumors.